Toward a chronotherapy of ovarian cancer with taxol. Part I: Basic background.
Cornélissen
G
G
University of Minnesota, Minneapolis.
Halberg
E
E
Long
H J
HJ
Prem
K
K
Bakken
E
E
Touitou
Y
Y
Elg
S
S
Haus
E
E
Halberg
F
F
D000470:Alkaloids / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000097:blood; D002909:Chronobiology Phenomena; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D017239:Paclitaxel
D000470:Alkaloids; D015295:Antigens, Tumor-Associated, Carbohydrate; D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D017239:Paclitaxel